A PILOT STUDY ON IDENTIFICATION AND MANAGEMENT OF DRUG INDUCED SEXUAL DYSFUNCTION: A COLLABORATIVE APPROACH BY CLINICAL PHARMACIST AND PSYCHIATRIST

IDENTIFICATION AND MANAGEMENT OF DRUG INDUCED SEXUAL DYSFUNCTION

  • BILESH SHAKYA Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, Karnataka 570015, India
  • TIRIN BABU Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, Karnataka 570015, India
  • MOHAMED SHAFI P. Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, Karnataka 570015, India
  • VEMURI TEJASRI Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, Karnataka 570015, India
  • JUNY SEBASTIAN Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, Karnataka 570015, India
  • SHIVANANDA MANOHAR J. Department of Psychiatry, JSS Medical College and Hospital, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India
  • JISHA MYALIL LUCCA Department of Pharmacy Practice, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia

Abstract

Objective: To assess the role of clinical pharmacists in the identification and management of drug-induced sexual dysfunction in collaboration with the psychiatrist and also to determine the prevalence and pattern of drug-induced sexual dysfunction, identify nature and extend of drug-induced sexual dysfunction, and assess the pattern of management of drug-induced sexual dysfunction.


Methods: This periodic prevalence interventional study was carried out among patients who visited the psychiatric department of a university hospital over three month’s period. Patients were screened for sexual dysfunction using the Arizona Sexual Experience Scale (ASEX) by study pharmacists.


Results: Of the 100 patients reviewed, only 50% of subjects met the study criteria. Depression (42%) was the most common clinical diagnosis among the study patients. The overall prevalence of drug-induced sexual dysfunction was 16%. A higher incidence of drug-induced sexual dysfunction was observed in men (62.5%). Decrease libido (40%) was the most prominently observed drug-induced sexual dysfunction in both genders. Antidepressant (50%) was the most common class of drugs implicated in sexual dysfunction. Drug-induced sexual dysfunction was pharmacologically managed with vaginal lubrication (40%), Tadalafil (20%) and Tadalafil+Dapoxetine combination (40%).


Conclusion: With this study, provided a vision, further how prospective studies in this arena may be carried out for better understanding drug-induced sexual dysfunction and how a clinical pharmacist can contribute for better health care of patients in the sex clinic by collaborating with medical practitioners.

Keywords: Sexual dysfunction, Drug-induced sexual dysfunction, Prevalence, Clinical Pharmacist’s Role, Sex clinic

Downloads

Download data is not yet available.

References

1. Chunder R. Sexual dysfunction: an approach for the pharmacist. SA Pharm J 2011;78:18-21.
2. Mkele G. A review of medicines that affect sexual performance. SA Pharm J 2014;81:34-7.
3. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44.
4. Lucca JM, Ramesh M, Ram D, Kurian J, Mathew N. Psychotropic medication-induced sexual dysfunction and its interference with patient's daily performance: a cross-sectional study. Egyptian J Psychiatry 2016;37:36.
5. Conaglen HM, Conaglen JV. Drug-induced sexual dysfunction in men and women. Aust Prescr 2013;36:42.
6. Boora K, Chiappone K, Dubovsky SL. Oxcarbazepine-induced reversible anorgasmia and ejaculatory failure: a case report. Prim Care Companion J Clin Psychiatry 2009;11:173-4.
7. Calabro RS, Ferlazzo E, Italiano D, Bramanti P. Dose-dependent oxcarbazepine-related anorgasmia. Epilepsy Behav 2010; 17:287-8.
8. Calabro RS, Italiano D, Pollicino P, Bramanti P. Oxcarbazepine-related retrograde ejaculation. Epilepsy Behav 2012;25:174-5.
9. Martin Morales A, Ibanez J, Machuca M, Pol Yanguas E, Schnetzler G, Renedo VP. The EPIFARM study: an observational study in 574 community pharmacies in Spain characterizing patient profiles of men asking for erectile dysfunction medication. J Sex Med 2010;7:3153-60.
10. Mohandas E. Roadmap to Indian psychiatry. Indian J Psychiatry 2009;51:173.
11. Goldstein I, Krane RJ. Drug-induced sexual dysfunction. World J Urol 1983;1:239-43.
12. Gregorian Jr RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002;36:1577-89.
13. Lucca JM, Kurian J, Ramesh M, Ram D. Appraisal of clinical pharmacy services in the mental health unit of a South Indian tertiary care hospital. World J Pharm Pharm Sci 2014;3:780-91.
14. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66.
15. Serretti A, Chiesa A. Antidepressivi e disfunzione sessuale: epidemiologia, meccanismi e strategie di trattamento. Giornale Italiano Psicopatologia 2010;16:104-13.
16. La Torre A, Giupponi G, Duffy DM, Pompili M, Grozinger M, Kapfhammer HP, et al. Sexual dysfunction related to psychotropic drugs: a critical review–part I: antidepressants. Pharmacopsychiatry 2013;46:191-9.
17. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Human psychopharmacology. Hum Psychopharmacol 2008;23:201-9.
18. Macdonald S, Halliday J, MacEwan T, Sharkey V, Farrington S, Wall S, et al. Nithsdale schizophrenia surveys 24:sexual dysfunction: case-control study. Br J Psychiatry 2003;182:50-6.
19. Fan X, Henderson DC, Chiang E, Briggs LB, Freudenreich O, Evins AE, et al. Sexual functioning, psychopathology and quality of life in patients with schizophrenia. Schizophr Res 2007;94:119-27.
20. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982;170:463-7.
21. Fujii A, Yasui Furukori N, Sugawara N, Sato Y, Nakagami T, Saito M, et al. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:288-93.
22. Knegtering H, Blijd C, Boks M. Sexual dysfunction and prolactin levels in patients using risperidone or olanzapine. Schizophr Res 2000;41:196.
23. La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grozinger M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 2013;46:201-8.
24. Patnaik S, Polimati H, Pragada R. Erectile dysfunction and its pharmacology: an overview. Asian J Pharm Clin Res 2017;10:17-23.
25. Shekar D, Vazir M, Kempanna B, Miryala S, Subedi A. Effect of yohimbine on clomipramine-induced sexual dysfunction in male rats. Asian J Pharm Clin Res 2017;10:92.
26. Dossenbach M, Dyachkova Y, Pirildar S, Anders M, Khalil A, Araszkiewicz A, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study. Eur Psychiatry 2006;21:251-8.
27. Calabro RS, Marino S, Bramanti P. Sexual and reproductive dysfunction associated with antiepileptic drug use in men with epilepsy. Expert Rev Neurother 2011;11:887-95.
Statistics
292 Views | 152 Downloads
Citatons
How to Cite
SHAKYA, B., T. BABU, M. SHAFI P., V. TEJASRI, J. SEBASTIAN, S. MANOHAR J., and J. M. LUCCA. “A PILOT STUDY ON IDENTIFICATION AND MANAGEMENT OF DRUG INDUCED SEXUAL DYSFUNCTION: A COLLABORATIVE APPROACH BY CLINICAL PHARMACIST AND PSYCHIATRIST”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, no. 2, Dec. 2019, pp. 32-37, doi:10.22159/ijpps.2020v12i2.34334.
Section
Original Article(s)